Jardiance Lawyers No Longer Reviewing New Lawsuits

Jardiance (empagliflozin) is a diabetes drug introduced by Boehringer Ingelheim in 2014, which is part of a class of medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors.

Side effects of Jardiance have been linked to a potential risk of serious and potentially life-threatening injuries, including:

  • Kidney Failure
  • Diabetic Ketoacidosis, Ketosis or Acidosis
  • Heart Attack
  • Stroke
  • Wrongful Death

The lawyers at Saiontz & Kirk, P.A. are no longer reviewing potential Jardiance cases. This page is maintained for informational purposes only.

RELATED CASES: Potential Invokana lawsuits are still being evaluated for individuals who have experienced amputation problems following use of this similar diabetes drug.

Jardiance Ketoacidosis Problems

Jardiance was approved by the FDA in August 2014. It is a member of a new class of diabetes drugs introduced in the U.S. known as sodium-glucose co-transporter 2 (SGLT2) inhibitors, which also includes the medications Invokana, Invokamet, Farixga, Glyxambi and Xigduo XR.

After less than one year on the market, the FDA issued a warning about the potential link between Jardiance and ketoacidosis, which involves the the accumulation of high levels of acid in the blood.

Also known as DKA (Diabetic Ketoacidosis), Ketosis or Acidosis this potential Jardiance side effect may cause users to suffer severe medical complications, with symptoms like:

  • Difficulty Breathing
  • Nausea or Vomiting
  • Abdominal Pain
  • Confusion, Fatigue or Sleepiness

In a drug safety communication issued in May 2015, the FDA indicated that it has identified reports of users of Jardiance or other SGLT2 diabetes drugs requiring emergency room treatment or hospitalization due to high levels of acid in the blood. In December 2015, the agency announced that stronger Jardiance warnings will be required about the importance of stopping treatment and seeking immediate medical attention if symptoms of ketoacidosis on Jardiance are seen.

Jardiance ketoacidosis lawsuits were reviewed for users hospitalized as a result of this serious condition, alleging that the drug makers withheld information from consumers and the medical community. If stronger warnings had been provided earlier, many individuals may have been able to avoid these potentially life-threatening Jardiance problems. New cases are no longer being accepted. This page is maintained for informational purposes only.

Jardiance Kidney Failure Risk

SGLT2 inhibitors like Jardiance work in a different way than other diabetes drugs, impacting the normal function of the kidney to increase the amount of sugar excreted in the urine. This was designed to increase glucose production and lower blood glucose levels among diabetics. However, it may be the cause of Jardiance kidney problems.

Adverse event reports submitted on behalf of users of the similar type 2 diabetes drug Invokana suggest that users may face a risk of kidney toxicity from Jardiance, which users of this class of medications reporting a high number of cases involving:

  • Kidney Failure
  • Kidney Impairment
  • Kidney Stones
  • Urinary Tract Infections
  • Abnormal Weight Loss
  • Hypersensitivity Reactions

Based on the mechanism of action, it appears that the link between Jardiance and kidney failure was known or should have been suspected before the medication was ever introduced.

The new FDA warnings announced in December 2015 also urge patients to seek immediate medical assistance if they have signs of a urinary tract infection, as this could be an indication of a more dangerous blood or kidney infection that may lead to kidney failure and even death.

Jardiance Class Action Lawyers

It appears that Boehringer Ingelheim, the makers of Jardiance, placed their desire for profits before consumer safety by rushing this new-generation diabetes drug onto the market. The Jardiance lawyers at Saiontz & Kirk, P.A. are no longer accepting new cases for injuries caused by this medication. This page is maintained for informational purposes only.